Oncolytics Biotech Inc

Oncolytics insider trades reveal disciplined Rule 10b5‑1 strategy, confidence in its REOLYSIN platform and a focus on liquidity as the oncology pipeline expands.

Insider buy by Oncolytics’ SVP signals confidence in its Reovirus‑based cancer therapy, REOLYSIN, and its clinical‑trial progress toward future approvals.

Oncolytics Biotech insider buying signals executive confidence—discover how strategic purchases of ADS by senior VP Lee Chan Henry could hint at future stock upside and key milestones.

Oncolytics insider buying signals growing confidence in its reovirus platform, with promising market access and clinical milestones but notable risks.

Oncolytics Biotech’s CEO and top execs are buying more shares—an insider confidence boost tied to its REOLYSIN pipeline, hinting at future growth despite current volatility.

Oncolytics’ CEO and senior execs buy shares, boosting confidence in its reovirus pipeline and upcoming Phase 2 results that could lift the low‑valuation biotech’s prospects.

Oncolytics insider buys reveal confidence after FDA Fast‑Track approval; investor insight on potential $200‑$400 M revenue and cautious strategy.

Oncolytics Biotech insider buying shows long‑term confidence in its reovirus platform, regulatory shift to Nevada, and patent expansion—signals to watch for future upside.